MannKind (MNKD) Label Extension and Priority Review Could be Transformative - BTIG
Tweet Send to a Friend
BTIG analyst Robert Hazlett reiterated a Buy rating and $4.00 price target on MannKind (NASDAQ: MNKD) after United Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
